Royalty Pharma PLC
NASDAQ:RPRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Royalty Pharma PLC
NASDAQ:RPRX
|
US |
|
United Therapeutics Corp
NASDAQ:UTHR
|
US |
|
CITIC Securities Co Ltd
SSE:600030
|
CN |
|
SLM Corp
NASDAQ:SLM
|
US |
|
F
|
Fastenal Co
XETRA:FAS
|
US |
|
S
|
Societe Generale SA
OTC:SCGLF
|
FR |
|
GomSpace Group AB
LSE:0GE8
|
SE |
|
Kinross Gold Corp
TSX:K
|
CA |
|
Canyon Resources Ltd
ASX:CAY
|
AU |
|
A
|
Adecco Group AG
SIX:ADEN
|
CH |
|
Eni SpA
MIL:ENI
|
IT |
Wall St Price Targets
RPRX Price Targets Summary
Royalty Pharma PLC
According to Wall Street analysts, the average 1-year price target for RPRX is 58.38 USD with a low forecast of 46.46 USD and a high forecast of 69.3 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RPRX's stock price target?
Price Target
58.38
USD
According to Wall Street analysts, the average 1-year price target for RPRX is 58.38 USD with a low forecast of 46.46 USD and a high forecast of 69.3 USD.
What is the Revenue forecast for Royalty Pharma PLC?
Projected CAGR
16%
Over the last 7 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 3 years is 16%.
What is the Operating Income forecast for Royalty Pharma PLC?
Projected CAGR
12%
Over the last 7 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 8 years is 12%.
What is the Net Income forecast for Royalty Pharma PLC?
Projected CAGR
31%
Over the last 7 years, the compound annual growth rate for Net Income has been -8%. The projected CAGR for the next 7 years is 31%.
